PM1183 ( Lurbinectedin ) . Fase III SCLC en la ELCC 2017 | European Lung Cancer Conference . 5-8 May 2017, Geneva, Switzerland .

Twit de José Antonio // ELCC-17 .








Dra Noemí Reguart talking about new therapies for SCLC.




PhrmMar Lurbinectedin shows ORR 67% and PhIII ATLANTIS trial is recruiting.